Patents by Inventor Mark Parrington

Mark Parrington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RESPIRATORY SYNCTIAL VIRUS RNA VACCINE
    Publication number: 20230302112
    Abstract: The present disclosure provides a respiratory syncytial virus (RSV) vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding an RSV F protein antigen, and methods of eliciting an immune response by administering said vaccine.
    Type: Application
    Filed: November 4, 2022
    Publication date: September 28, 2023
    Inventors: Danilo Casimiro, Hardip Rajeshbhai Gopani, Joshua DiNapoli, Linong Zhang, Mark Parrington, Rebecca L. Goldman, Sudha Chivukula, William Scott Gallichan
  • EXPRESSION AND CONFORMATIONAL ANALYSIS OF ENGINEERED INFLUENZA HEMAGGLUTININ
    Publication number: 20170121373
    Abstract: The present invention provides, among other things, compositions and methods for analyzing the expression and conformation of engineered influenza hemagglutinin In particular, the present invention provides methods of screening in silico designed HA antigens using neutralizing antibody panels specific to conserved epitopes. In some embodiments, the HAs are down selected for inclusion in universal influenza vaccines based upon their binding to neutralizing antibody panels in immunostaining assays.
    Type: Application
    Filed: May 29, 2015
    Publication date: May 4, 2017
    Inventors: Guadalupe CORTES-GARCIA, Timothy ALEFANTIS, Mark PARRINGTON
  • Replication-defective flavivirus vaccines and vaccine vectors
    Patent number: 9217158
    Abstract: This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: December 22, 2015
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Konstantin V. Pugachev, Maryann Giel-Moloney, Harold Kleanthous, Mark Parrington, Linong Zhang
  • Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
    Patent number: 8946174
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: February 3, 2015
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
  • Multi-antigen vectors of melanoma
    Patent number: 8911991
    Abstract: The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: December 16, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, James Tartaglia, Mark Parrington, Dennis L. Panicali, Linda Gritz
  • Modified CEA/B7 vector
    Patent number: 8562970
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: October 22, 2013
    Assignee: Sanofi Pasteur Limited
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda Gritz, Patricia Greenhaigh
  • Modified CEA nucleic acid and expression vectors
    Patent number: 8530442
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: September 10, 2013
    Assignee: Sanofi Pasteur Limited
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS
    Publication number: 20130101625
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Application
    Filed: June 25, 2012
    Publication date: April 25, 2013
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • Tumor Antigens for the Prevention and/or Treatment of Cancer
    Publication number: 20130011422
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: January 10, 2013
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
  • Modified CEA nucleic acid and expression vectors
    Patent number: 8236776
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: August 7, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • Tumor antigens for prevention and/or treatment of cancer
    Patent number: 8207314
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: June 26, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
  • Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
    Publication number: 20120128713
    Abstract: Replication-defective vaccine vectors against respiratory syncytial virus (RSV) are disclosed. Corresponding compositions and methods employing the vaccine vectors are also disclosed.
    Type: Application
    Filed: March 16, 2010
    Publication date: May 24, 2012
    Applicants: Sanofi Pasteur Limited, Sanofi Pasteur Biologics Co.
    Inventors: Konstantin V. Pugachev, Alexander A. Rumyantsev, Maryann Giel-Moloney, Mark Parrington, Linong Zhang
  • Tumor antigens Bfa5 for prevention and/or treatment of cancer
    Patent number: 8021664
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: September 20, 2011
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Devender Singh-Sandhu
  • TUMOR ANTIGENS BFA4 AND BCY1 FOR PREVENTION AND / OR TREATMENT OF CANCER
    Publication number: 20110117640
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: September 23, 2010
    Publication date: May 19, 2011
    Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
  • Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
    Patent number: 7851213
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: December 14, 2010
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
  • MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS
    Publication number: 20100285065
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Application
    Filed: March 2, 2010
    Publication date: November 11, 2010
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • TUMOR ANTIGEN BFY3 FOR PREVENTION AND/OR TREATMENT OF CANCER
    Publication number: 20100278848
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: April 15, 2004
    Publication date: November 4, 2010
    Applicant: AVENTIS PASTEUR, INC.
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
  • Modified CEA nucleic acid and expression vectors
    Patent number: 7786278
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: August 31, 2010
    Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
  • Modified KSA and Uses Thereof
    Publication number: 20090156519
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: December 23, 2004
    Publication date: June 18, 2009
    Applicants: AVENTIS PASTEUR, INC., THERION BIOLOGICS, INC.
    Inventors: Neil Berinstein, James Tartaglia, Mark Parrington, Dennis Panicali, Linda Gritz
  • Tumor Antigens Bfa5 For Prevention And/Or Treatment Of Cancer
    Publication number: 20080138365
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: April 15, 2004
    Publication date: June 12, 2008
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Devender Singh-Sandhu